- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer -

Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans.

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway -

Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.

The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -

Discover today’s top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens.

- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer -

Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.

- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors -

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients -

- Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients -

A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.

Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate and 80% disease control rate.

- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment -

CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from September 4-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, Michael Bookman, Chief Legal Officer and Secretary and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.

- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -

- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104’s path to U.S. FDA submission for PDAC -